The Zacks Analyst Blog Highlights: Mylan, Abbott Laboratories, Ista Pharmaceuticals, Johnson & Johnson and Teva Pharmaceuticals

Saturday, May 28, 2011 General News
Email Print This Page Comment bookmark
Font : A-A+

CHICAGO, May 27, 2011 /PRNewswire/ -- announces the list of stocks featured in the Analyst Blog. Every day the

Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Mylan Inc. (NYSE: MYL), Abbott Laboratories (NYSE: ABT), Ista Pharmaceuticals Inc
(Nasdaq: ISTA), Johnson & Johnson (NYSE: JNJ) and Teva Pharmaceuticals (Nasdaq: TEVA).


Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter:

Here are highlights from Thursday's Analyst Blog:

Mylan Launches New Generics

Mylan Inc.'s (NYSE: MYL) generic portfolio continued to be boosted with the launch of the generic version of Xanodyne Pharmaceutical's pain reliever Roxicodone. The generic has been launched under a development and supply agreement with Coastal Pharmaceuticals.

The product recorded sales of $325 million in US for the twelve months endied March 31, 2011 according to data released by IMS Health.

We note that the launch of the generic version of the pain reliever is the latest in the series of generic launches at Mylan. A couple of days ago the company, which is one of the largest generic and specialty pharmaceutical companies across the globe, launched its generic version of Abbott Laboratories' (NYSE: ABT) Depakote Sprinkle Capsules for treating seizures.

The product recorded sales of $89 million in US for the twelve months ended March 31, 2011 according to data released by IMS Health.

Mylan had also recently launched the generic versions of Ista Pharmaceuticals Inc's (Nasdaq: ISTA) Xibrom ophthalmic solution and Johnson & Johnson's (NYSE: JNJ) schizophrenia drug Risperdal.

The generic segment which develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule or transdermal patch forms, accounts for the bulk of the revenues at Mylan. Management stated that it currently has167 abbreviated new drug applications (ANDAs) pending approval by the US Food and Drug Administration (FDA) targeting $100.3 billion in branded sales.

Mylan believes that approximately 45 of the pending ANDAs are first-to-file opportunities and represent a market opportunity in excess of $25.8 billion (in terms of branded sales).

Our Recommendation

We currently have a Neutral recommendation on Mylan. The company carries a Zacks #3 Rank (Hold rating) in the short-run. Mylan is one of the leading players in the US generics market.

The company holds immense potential as many blockbuster drugs are slated to lose patent exclusivity in the forthcoming period. We are encouraged by Mylan's robust generic product pipeline.

However, competition in the generic segment is strong with players like Teva Pharmaceuticals (Nasdaq: TEVA) in the field. We also remain concerned about the lack of growth in the European generics business. We intend to remain watchful until we get better visibility on top-line growth prospects in Europe.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today:

About Zacks is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at

Visit for information about the performance numbers displayed in this press release.

Follow us on Twitter:

Join us on Facebook:

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Media ContactZacks Investment Research800-767-3771 ext. 9339support@zacks.com

SOURCE Zacks Investment Research, Inc.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store